The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO TAT 2022 | Unmet needs in NSCLC that EGFR inhibitor BDTX-1535 aims to address
Matthew Lucas, PhD, Black Diamond Therapeutics, Cambridge, MA, discusses the rationale of using BDTX-1535 to treat non-small cell lung cancer. Central nervous system (CNS) metastases can occur in approx. 50% of patients with lung cancer. Therefore, an EGFR inhibitor which can also target CNS metastases could provide a good therapeutic benefit to these patients. BDTX-1535 is aimed at two key subsets of patients with NSCLC: those with intrinsic resistance mutations and those with acquired resistance (C797S mutation) after treatment with other inhibitors. Dr Lucas also discusses the benefits and limitations of other EGFR inhibitors. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.
